期刊文献+

内毒素诱导非小细胞肺癌细胞增殖及其机制

Effects of Endotoxin on Tumor Proliferation in the Non-Small Cell Lung Cancer and Underlying Mechanisms
原文传递
导出
摘要 目的:研究内毒素对体外培养非小细胞肺癌(NSCLC)细胞株A549细胞增殖的影响及其机制。方法:不同浓度脂多糖(LPS)进行8-48h干预,MTT及细胞计数法检测其对A549细胞增殖的影响;EGFR中和抗体或COX-2抑制剂与LPS联合干预,检测其对A549细胞增殖及PGE2的影响。结果:LPS可引发A549细胞MTT活性和细胞计数显著增加,且呈现时间和剂量依赖性。LPS还可诱发PGE2水平显著升高。药物干预结果显示,抑制COX-2或EGFR可明显逆转LPS所引发的细胞增殖和PGE2水平升高趋势。结论:LPS可能通过激活EGFR和COX-2信号途径,诱导体外培养的非小细胞肺癌细胞增殖分化。肺部感染可能会加速非小细胞肺癌进展,并可能造成不良预后。 Objective: To investigate the effect of endotoxin on tumor proliferation in the non-small cell lung cancer and the underlying mechanisms. Methods: Different concentrations ofLipopolysaccharide (LPS) were intervented from 8 to 48 h. The effection of LPS on the proliferation of A549 cells with MTT and cell counting were tested. The intervention effect of the combination of EGFR neutralizing antibody or COX-2 inhibitors with LPS on the proliferation of A549 cells and PGE2 were tested. Results: LPS induced a time- and dose-dependent increase in proliferation of A549 cells as quantified by MTS activity and cell counting. Large amounts of COX-2-derived prostaglandin (PG) E2 were secreted from LPS-stimulated A549 cells. Pharmacological interventions revealed that inhibition of COX-2 and EGFR activity in A549 cells severely attenuated both PGE2 release and proliferation in response to LPS. Conclusion: LPS induces proliferation of NSCLC cells in vitro inhuman NSCLC specimen via EGFR- or COX-2-signaling. Pulmonary infection may thus directly induce tumor progression in NSCLC.
出处 《现代生物医学进展》 CAS 2014年第8期1449-1451,共3页 Progress in Modern Biomedicine
关键词 肺癌 内毒素 肿瘤增殖 Lung cancer Endotoxin Tumor proliferation
  • 相关文献

参考文献22

  • 1Pisani P, Parkin DM, Munoz N, et al. Cancer and infection: estimated of the attributable fraction in 1990 [J]. Cancer Epidemiol Biomarkers Prev, 2009, 6(1): 387-400.
  • 2Vogelmann R, Amieva MR. The role of bacterial patho-gens in cancer [J]. Curr Opin Microbiol, 2007, 10( 1):76-81.
  • 3Putinati S, Trevisani L, Gualandi M, et al.Pulmonary infections in lung cancer patients at diagnosis[J]. Lung Cancer, 1994, 11 (1): 342-349.
  • 4Berghmans T, Sculier JP, Klastersky J. A prospective study of infections in lung cancer patients admitted to the hos-pital [J]. Chest, 2003, 124(1): 114-120.
  • 5Perlin E, Bang KM, Shah A, et al. The impact of pulmonary infections on the survival of lung cancer patients[J]. Cancer, 2009, 66(3): 593-596.
  • 6Coussens LW, Werb Z. Inflammation and cancer[J]. Nature, 2002, 420 (1): 860-867.
  • 7Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation [J]. Nature, 2008, 454(1): 436-444.
  • 8Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxy genase-2 in human lung carcinoma [J]. Cancer Res, 2008, 58 (10): 4997-5001.
  • 9Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarci nomas[J]. Clin Cancer Res, 2009, 5(2): 1001-1005.
  • 10McLemore TL, Hubbard WC, Litterst CL, et al. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients[J]. Cancer Res, 1988, 48(12): 3140-3147.

二级参考文献15

共引文献754

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部